Board of Directors
Chairman of the Board
Partner, AVEGO Healthcare Capital
Mr. Vandervort is a Partner at Avego Healthcare Capital, based in Atlanta, GA. His background ranges from numerous positions in the pharmaceutical services industry including the 3PL DDN Pharmaceutical Logistics and the ultra-orphan drug specialty pharmacy Centric Health Resources to leadership roles in business development for West-Ward Pharmaceuticals and IGI Laboratories (now Teligent, Inc.).
As a sales leader for DDN and Centric, Mr. Vandervort built a brand for each company as the service provider of choice, as seen in the rapid growth in new clients and profitability for both companies. Mr. Vandervort ran M&A for West-Ward and was part of the team that acquired Baxter’s multi-source injectable business as well as numerous products that expanded West-Ward’s R&D portfolio to include NDAs as well as paragraph IV challenges.
With IGI laboratories, Mr. Vandervort led multiple M&A transactions, including deals with Valeant and Concordia as well as the acquisition of the Canadian generic injectable company, Alveda Pharma, Inc. Mr. Vandervort has a BA from Bethany College in Bethany, WV and an MA from Duquesne University in Pittsburgh, PA.
Partner, AVEGO Healthcare Capital
Prior to joining Avego, Mr. Flexner was an investment professional with Metalmark Capital, where he focused on majority recap and growth investments across multiple industries, including healthcare. Mr. Flexner began his career as an investment banker in the Global Healthcare Group at Morgan Stanley, where he executed multiple transactions across the life sciences and healthcare services industries. Mr. Flexner graduated from Dartmouth College with a BA degree in Economics and Chemistry.
Senior Managing Director, Melkonian Healthcare Capital
Terence Cooke is a Senior Managing Director of Melkonian Capital and a member of the Investment Committee. Prior to joining the firm, Terence was an equity portfolio manager at Harvard Management Company. Previously, he worked at Ford Financial Fund and focused on private investments in distressed banks.
Earlier in his career, Terence invested in equities at Tudor Investment Corporation and had sell-side equity research roles at Goldman Sachs and Sanford C. Bernstein.
Terence has a B.A. in Economics from Lafayette College and an M.B.A with a concentration in finance from the Wharton School at the University of Pennsylvania.
Independent Board Member
Co-Founder, President & Chief Executive Officer, Sentynl Therapeutics
Mr. Heck is founder, CEO and a member of the Board of Directors of Sentynl Therapeutics, Inc, which was acquired by Zydus Cadila Healthcare Ltd in January 2017. Prior to Sentynl, Mr. Heck co-founded Victory Pharmaceuticals, Inc. and served as CEO and as a member of its Board of Directors.
Before founding Victory, Mr. Heck served as Vice President of Sales at Biovail Pharmaceuticals, where he built and managed its U.S. commercial operations. Mr. Heck joined Biovail in 2000 through its acquisition of DJ Pharma, where he served on the founding management team in a variety of commercial capacities, including Vice President of Sales.
Before DJ, Mr. Heck held a variety of commercial positions in sales management, marketing, and managed care functions at Dura Pharmaceuticals (acquired by Elan). Prior to joining Dura, he held multiple commercial roles at Dial Corporation. Mr. Heck graduated with honors from the University of South Carolina with a B.A. in Marketing.
Jerry St. Peter
Chief Executive Officer and Co-Founder, Eyevance Pharmaceuticals
Jerry St. Peter is the Co-Founder, CEO and Director of Eyevance Pharmaceuticals. Since inception of the company in September 2017, Mr. St. Peter manages and leads Eyevance’s business operations, communicates on behalf of the company, guides the development of Eyevance’s short, mid and long term strategies and galvanizes the vision across the organization.
Mr. St. Peter brings over 30 years of Ophthalmic executive leadership impacting strategic planning, commercial operations, financial management, business development, and overall general management. The hallmark and passion of his career is serving his customers – the doctors and colleagues he is loyal to.
Prior to co-founding Eyevance, Mr. St. Peter was the Vice President and Head of Sun Pharmaceuticals’ newly formed Ophthalmics division. Previous to Sun, he was the Executive Vice President and General Manager for Nicox’s Ophthalmic business in the United States and formerly served as the Senior Vice President and Head of the Ophthalmic division at Inspire Pharmaceuticals.
Mr. St. Peter holds a Bachelor’s of Science in Health from the University of Massachusetts – Lowell and was recently distinguished with the 2017 University Alumni Lifetime Achievement Award for the College of Health Sciences.